WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

BACKGROUND: Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial and continuous improvement of outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Daniel, Nitz, Ulrike, Gluz, Oleg, Kates, Ronald E, Schinkoethe, Timo, Staib, Peter, Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765940/
https://www.ncbi.nlm.nih.gov/pubmed/23958221
http://dx.doi.org/10.1186/1745-6215-14-261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3765940/
https://www.ncbi.nlm.nih.gov/pubmed/23958221
http://dx.doi.org/10.1186/1745-6215-14-261

Ejemplares similares